Drug Trial Radar · NCT06706427
Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy Subjects
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12
Actual
Start
Mar 21, 2024
Primary completion
Nov 30, 2025
Study completion Sep 26, 2029
Sponsor
- Lead sponsor
- NGGT (Suzhou) Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the safety, tolerability, and efficacy of subretinal injection of NGGT001 in patients with Bietti Crystalline Corneoretinal Dystrophy (BCD) and to recommend the optimal dosage for future clinical administration.
Conditions
- Bietti Crystalline Corneoretinal Dystrophy
Interventions
NGGT001Biological
Using a recombinant adeno-associated virus (AAV) vector to deliver the gene CYP4V2 via subretinal injection for the treatment of crystalline retinal degeneration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) from baseline to 52 weeks.Time frame: 52 weeks
- Evaluate the improvement in BCVA compared to baseline at Week 12, 26 and 52.Time frame: Week 12, Week 26 and Week 52
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Southwest Hospital/Southwest Eye Hospital, Third Military Medical University (Army Medical University)
Chongqing, Chongqing Municipality, China
Xiamen Eye Center of Xiamen University
Xiamen, Fujian, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.